2022-08-13 09:08
However, in a follow up report, WSJ said that the deal is unlikely to finalize before the pharma giant’s earnings date on July 28.The reasons for the delay are said to be an upcoming data readout for the Seagen’s (SGEN) bladder-cancer therapy Padcev and an impending outcome of a lawsuit between the company and Japanese drugmaker Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) over royalty payments.